ALLO-501A
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ALLO-501A, covering 2025-12-31 to 2026-03-04. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) [Phase 1, Phase 2]